Global impact of ESC Guidelines Thank you for taking part in this survey which will take approximately 12 minutes. Our goal is to assess the availability of interventions / products recommended in ESC guidelines. Every page of this survey represents a different category.Before we continue, may we just remind you of our Code of Conduct for ESC surveys? We comply with the European General Data Protection Regulation (GDPR) 2016/679. Any personal data processed in connection with this survey will be treated confidentially, will not be disclosed to any third party and will only be used by the ESC for the purposes of market research and not for promotion. Survey results will be kept for a maximum of 24 months for analysis and quality control purposes. We take all reasonable care to prevent any unauthorized access to your personal data. We respect your privacy and your right to access, modify, or remove your personal data. At any time, you can ask to know what personal data is being held. If you have any questions about data protection or require further information, please contact our data protection officer (DPO) at dpo@escardio.org. You have the right to end your participation in this survey at any time. Question Title * 1. Please confirm that you have read the above and agree to participate in this survey. Yes No Question Title * 2. Please indicate your name Name Question Title * 3. What is your country of work? France Germany Russian Federation Syrian Arab Republic Ukraine United Kingdom Afghanistan Argentina Australia Bangladesh Brazil Canada Jamaica Chile China Colombia Costa Rica Cuba Dominican Republic Ecuador Guatemala United Arab Emirates United Arab Emirates Hong Kong India Indonesia Iran (Islamic Republic of) Iraq Japan Jordan Kenya Korea (Republic of) Macao Malaysia Mauritius Mexico Mongolia Nigeria Oman Pakistan Panama Paraguay Peru Philippines Saudi Arabia Singapore South Africa Sudan Taiwan Thailand Uruguay Venezuela (Bolivarian Republic of) Vietnam New Zealand Albania Algeria Armenia Austria Azerbaijan Belarus Belgium Bosnia and Herzegovina Bulgaria Croatia Cyprus Czechia Denmark Egypt Estonia Finland Georgia Greece Hungary Iceland Ireland Israel Italy Kazakhstan Kosovo Rep. of Kyrgyzstan Latvia Lebanon Libya Lithuania Luxembourg Malta Moldova Rep. of Montenegro Morocco Netherlands North Macedonia Norway Poland Portugal Romania San Marino Serbia Slovakia Slovenia Spain Sweden Switzerland Tunisia Turkey Ukraine Uzbekistan Other (please specify) Pharmaceutical interventions / Vasoactive drugs & antihypertensives Question Title * 4. Are the following treatments available in your country?Please rate from 1 to 4, where: 1=Not at all available in my country 2=Mostly/often unavailable (in specific settings / areas / patients) 3= Mostly/often available (in specific settings / areas / patients) 4=Fully available (in most settings, regions and for most patients) 1 2 3 4 ACE inhibitors ACE inhibitors 1 ACE inhibitors 2 ACE inhibitors 3 ACE inhibitors 4 ARBs ARBs 1 ARBs 2 ARBs 3 ARBs 4 Dihydropyridine calcium channel blockers Dihydropyridine calcium channel blockers 1 Dihydropyridine calcium channel blockers 2 Dihydropyridine calcium channel blockers 3 Dihydropyridine calcium channel blockers 4 Diuretics Diuretics 1 Diuretics 2 Diuretics 3 Diuretics 4 Midodrine Midodrine 1 Midodrine 2 Midodrine 3 Midodrine 4 Mineralocorticoid Receptor Antagonists Mineralocorticoid Receptor Antagonists 1 Mineralocorticoid Receptor Antagonists 2 Mineralocorticoid Receptor Antagonists 3 Mineralocorticoid Receptor Antagonists 4 NTG iv NTG iv 1 NTG iv 2 NTG iv 3 NTG iv 4 RAAS blockers RAAS blockers 1 RAAS blockers 2 RAAS blockers 3 RAAS blockers 4 Pharmaceutical interventions / Rhythm controlling drugs & Antiarrhythmics Question Title * 5. Are the following treatments available in your country?Please rate from 1 to 4, where: 1=Not at all available in my country 2=Mostly/often unavailable (in specific settings / areas / patients) 3= Mostly/often available (in specific settings / areas / patients) 4=Fully available (in most settings, regions and for most patients) 1 2 3 4 Adenosine Adenosine 1 Adenosine 2 Adenosine 3 Adenosine 4 Beta blockers Beta blockers 1 Beta blockers 2 Beta blockers 3 Beta blockers 4 Cellprolol Cellprolol 1 Cellprolol 2 Cellprolol 3 Cellprolol 4 Digoxin Digoxin 1 Digoxin 2 Digoxin 3 Digoxin 4 Flecainide Flecainide 1 Flecainide 2 Flecainide 3 Flecainide 4 Pharmaceutical interventions / Platelet inhibitors & anticoagulants Question Title * 6. Are the following treatments available in your country?Please rate from 1 to 4, where: 1=Not at all available in my country 2=Mostly/often unavailable (in specific settings / areas / patients) 3= Mostly/often available (in specific settings / areas / patients) 4=Fully available (in most settings, regions and for most patients) 1 2 3 4 Aspirin Aspirin 1 Aspirin 2 Aspirin 3 Aspirin 4 Clopidogrel Clopidogrel 1 Clopidogrel 2 Clopidogrel 3 Clopidogrel 4 P2Y12 inhibitors P2Y12 inhibitors 1 P2Y12 inhibitors 2 P2Y12 inhibitors 3 P2Y12 inhibitors 4 Polypill Polypill 1 Polypill 2 Polypill 3 Polypill 4 Prasugrel Prasugrel 1 Prasugrel 2 Prasugrel 3 Prasugrel 4 LMWH LMWH 1 LMWH 2 LMWH 3 LMWH 4 Thrombolytics Thrombolytics 1 Thrombolytics 2 Thrombolytics 3 Thrombolytics 4 VKA VKA 1 VKA 2 VKA 3 VKA 4 Pharmaceutical interventions / Lipid lowering drugs Question Title * 7. Are the following treatments available in your country?Please rate from 1 to 4, where: 1=Not at all available in my country 2=Mostly/often unavailable (in specific settings / areas / patients) 3= Mostly/often available (in specific settings / areas / patients) 4=Fully available (in most settings, regions and for most patients) 1 2 3 4 Cholesterol absorption inhibitor Cholesterol absorption inhibitor 1 Cholesterol absorption inhibitor 2 Cholesterol absorption inhibitor 3 Cholesterol absorption inhibitor 4 Ezetimibe Ezetimibe 1 Ezetimibe 2 Ezetimibe 3 Ezetimibe 4 Fibrates Fibrates 1 Fibrates 2 Fibrates 3 Fibrates 4 PCSK9 inhibitors PCSK9 inhibitors 1 PCSK9 inhibitors 2 PCSK9 inhibitors 3 PCSK9 inhibitors 4 Statins Statins 1 Statins 2 Statins 3 Statins 4 Unfractionated heparin Unfractionated heparin 1 Unfractionated heparin 2 Unfractionated heparin 3 Unfractionated heparin 4 Pharmaceutical interventions / Other drugs Question Title * 8. Are the following treatments available in your country?Please rate from 1 to 4, where: 1=Not at all available in my country 2=Mostly/often unavailable (in specific settings / areas / patients) 3= Mostly/often available (in specific settings / areas / patients) 4=Fully available (in most settings, regions and for most patients) 1 2 3 4 Corticosteroids Corticosteroids 1 Corticosteroids 2 Corticosteroids 3 Corticosteroids 4 Epidural Epidural 1 Epidural 2 Epidural 3 Epidural 4 Endothelial growth factor inhibitors Endothelial growth factor inhibitors 1 Endothelial growth factor inhibitors 2 Endothelial growth factor inhibitors 3 Endothelial growth factor inhibitors 4 Ergometrine Ergometrine 1 Ergometrine 2 Ergometrine 3 Ergometrine 4 Fludrocortisone Fludrocortisone 1 Fludrocortisone 2 Fludrocortisone 3 Fludrocortisone 4 Insulin Insulin 1 Insulin 2 Insulin 3 Insulin 4 Levodopa Levodopa 1 Levodopa 2 Levodopa 3 Levodopa 4 Metformin Metformin 1 Metformin 2 Metformin 3 Metformin 4 Oxytocin Oxytocin 1 Oxytocin 2 Oxytocin 3 Oxytocin 4 SGLT2 inhibitors SGLT2 inhibitors 1 SGLT2 inhibitors 2 SGLT2 inhibitors 3 SGLT2 inhibitors 4 Flu vaccinations Flu vaccinations 1 Flu vaccinations 2 Flu vaccinations 3 Flu vaccinations 4 Question Title * 9. If applicable, for all the pharmaceutical products above which are not available (1) or only partially available (2 or 3), could you please indicate the top 3 reasons for that?(please select 3 reasons maximum) Importation blocked / impossible Marketing discontinued Distribution problem Manufacturing problem Quality problem Unavailability of raw material Too expensive for institutions Too expensive for individuals/patients Not covered / reimbursed by healthcare system I do not know Other (please specify) Page1 / 12 8% of survey complete. Next
